REGENERX Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>RB</div>
RGRX -- USA Stock  

USD 0.60  0.01  1.69%

REGENERX BIOPHARMACEUTICA is scheduled to announce its earnings today. As many risky investors are excited about healthcare space, it is only fair to break down REGENERX BIOPHARMACEUTICALS based on its current volatility. We will evaluate why recent REGENERX BIOPHARMACEUTICA price moves suggest a bounce in December. This firm current probability of distress is over 95%. Are REGENERX BIOPHARMACEUTICA investors still optimistic?
Published over a week ago
View all stories for REGENERX BIOPHARMACEUTICA | View All Stories
Are investors happy with REGENERX BIOPHARMACEUTICA (OTC:RGRX) basic indicators?
The company holds a Beta of -0.727, which implies possible diversification benefits within a given portfolio. Let's try to break down what REGENERX's beta means in this case. As returns on the market increase, returns on owning REGENERX BIOPHARMACEUTICA are expected to decrease at a much lower rate. During the bear market, REGENERX BIOPHARMACEUTICA is likely to outperform the market. Although it is extremely important to respect REGENERX BIOPHARMACEUTICA current trending patterns, it is better to be realistic regarding the information on equity existing price patterns. The way of forecasting future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By evaluating REGENERX BIOPHARMACEUTICA technical indicators, you can today evaluate if the expected return of 0.0412% will be sustainable into the future. REGENERX BIOPHARMACEUTICA now holds a risk of 6.62%. Please check REGENERX BIOPHARMACEUTICA treynor ratio, as well as the relationship between the expected short fall and day median price to decide if REGENERX BIOPHARMACEUTICA will be following its historical price patterns.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include REGENERX BIOPHARMACEUTICA income statement, its balance sheet, and the statement of cash flows. Potential REGENERX BIOPHARMACEUTICA investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although REGENERX BIOPHARMACEUTICA investors may use each financial statement separately, they are all related. The changes in REGENERX BIOPHARMACEUTICA's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on REGENERX BIOPHARMACEUTICA's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of REGENERX BIOPHARMACEUTICA fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of REGENERX BIOPHARMACEUTICA performance into the future periods or doing a reasonable stock valuation. The intrinsic value of REGENERX BIOPHARMACEUTICA shares is the value that is considered the true value of the share. If the intrinsic value REGENERX is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares REGENERX BIOPHARMACEUTICA. Please read more on our fundamental analysis page.

Watch out for price decline

Please consider monitoring REGENERX BIOPHARMACEUTICA on a daily bases if you are holding a position in it. REGENERX BIOPHARMACEUTICA is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as REGENERX BIOPHARMACEUTICA stock to be traded above the $1 level to remain listed. If REGENERX BIOPHARMACEUTICA stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is REGENERX BIOPHARMACEUTICA's Liquidity

REGENERX BIOPHARMACEUTICA financial leverage refers to using borrowed capital as a funding source to finance REGENERX BIOPHARMACEUTICALS ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. REGENERX BIOPHARMACEUTICA financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between REGENERX BIOPHARMACEUTICA's total debt and its cash.

How REGENERX utilizes its cash?

To perform a cash flow analysis of REGENERX BIOPHARMACEUTICA, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash REGENERX BIOPHARMACEUTICA is receiving and how much cash it distributes out in a given period. The REGENERX BIOPHARMACEUTICA cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Purchase by Mauro Bove of 20880 shares of REGENERX BIOPHARMACEUTICA

Legal trades by REGENERX BIOPHARMACEUTICA insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
REGENERX insider trading alert for perchase of common stock warrant (right to buy) by Mauro Bove, the corporate stakeholder, on 20th of October 2020. This event was filed by Regenerx Biopharmaceutica with SEC on 2020-10-20. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of REGENERX BIOPHARMACEUTICA is not uncomon. There are few distinct groups of REGENERX BIOPHARMACEUTICA stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of REGENERX is distributed among investors.

Ownership Allocation

REGENERX BIOPHARMACEUTICA has a total of 133.44 Million outstanding shares. REGENERX BIOPHARMACEUTICA has substantial amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Retail Investors
51.55%
Insiders
48.26%
Retail Investors51.55
Insiders48.26
Institutions0.19

Will REGENERX BIOPHARMACEUTICA growth be rational after the rise?

The variance is down to 51.41 as of today. REGENERX BIOPHARMACEUTICALS is displaying above-average volatility over the selected time horizon. Investors should scrutinize REGENERX BIOPHARMACEUTICALS independently to ensure intended market timing strategies are aligned with expectations about REGENERX BIOPHARMACEUTICA volatility. REGENERX BIOPHARMACEUTICALS is a potential penny stock. Although REGENERX BIOPHARMACEUTICA may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in REGENERX BIOPHARMACEUTICALS. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

When is the right time to buy or sell REGENERX BIOPHARMACEUTICALS? Buying stocks such as REGENERX BIOPHARMACEUTICA isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. To conclude, as of the 13th of November 2020, we see that REGENERX BIOPHARMACEUTICA moves slightly opposite to the market. The company is undervalued with significantly high probability of distress within the next 24 months. However, our overall 30 days buy vs. sell advice on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of REGENERX BIOPHARMACEUTICALS. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com